Taiwan-based MLOps startup InfuseAI raises $4.3M Series A led by Wistron Corporation
23 Apr, 2021
– Brii Bio, a multi-national company developing innovative therapies for diseases with significant unmet medical needs and large public health burden, today announced completion of a Series C financing of US$155m.
– The financing was led by Invesco Developing Markets Fund, with significant additional funding provided by GIC and another global leading investment management organization, followed by Lake Bleu Capital and an Asia-based leading investment organization, as well as three current investors.
– Proceeds from the financing will be used to advance Brii Bio’s broad infectious diseases pipeline as well as the company’s CNS program.
– Brii Bio is currently conducting clinical studies in multiple infectious diseases, and is preparing to enter clinical-stage research in diseases of the central nervous system.